Edition:
United States

Rexahn Pharmaceuticals Inc (RNN)

RNN on American Stock Exchange

2.46USD
22 Sep 2017
Change (% chg)

$0.05 (+2.07%)
Prev Close
$2.41
Open
$2.38
Day's High
$2.48
Day's Low
$2.36
Volume
159,868
Avg. Vol
257,180
52-wk High
$7.10
52-wk Low
$1.27

Latest Key Developments (Source: Significant Developments)

Rexahn Pharmaceuticals reports Q2 earnings per share $0.04
Monday, 7 Aug 2017 09:00am EDT 

Aug 7 (Reuters) - Rexahn Pharmaceuticals Inc :Rexahn Pharmaceuticals reports second quarter 2017 financial and operational results.Q2 earnings per share $0.04.Rexahn Pharma - ‍Expects its cash, investments as of june 30, will be sufficient to fund cash flow requirements for current activities into late 2018​.Rexahn Pharma - ‍Cash and investments totaled approximately $26.8 million as of June 30, 2017, compared to approximately $20.3 million as of December 31, 2016​.Rexahn Pharma - ‍During H2 2017, plan to initiate additional clinical studies with RX-3117 in combination with Abraxane.  Full Article

Rexahn Pharmaceuticals announces $10 mln registered direct offering
Wednesday, 7 Jun 2017 08:50am EDT 

June 7 (Reuters) - Rexahn Pharmaceuticals Inc :Rexahn announces $10 million registered direct offering.Rexahn Pharmaceuticals Inc - net proceeds of offering will be used for further development of rexahn's lead clinical programs,.Rexahn Pharmaceuticals - entered agreements to purchase about 3.03 million shares of stock and warrants exercisable for up to about 1.52 million shares of stock.  Full Article

Rexahn Pharmaceuticals files for mixed shelf offering of up to $150 mln‍​
Friday, 26 May 2017 04:41pm EDT 

May 26 (Reuters) - Rexahn Pharmaceuticals Inc ::Rexahn Pharmaceuticals files for mixed shelf offering of up to $150 million - sec filing‍​.  Full Article

Rexahn says effects 1-for-10 reverse stock split
Friday, 5 May 2017 09:00am EDT 

May 5 (Reuters) - Rexahn Pharmaceuticals Inc ::Rexahn effects 1-for-10 reverse stock split.Previously announced 1-for-10 reverse stock split became effective today.  Full Article

Rexahn Pharmaceuticals reports Q1 loss per share $0.09
Thursday, 4 May 2017 09:00am EDT 

May 4 (Reuters) - Rexahn Pharmaceuticals Inc : :Rexahn Pharmaceuticals reports first quarter 2017 financial results and provides corporate update.Q1 loss per share $0.09.Q1 earnings per share view $-0.02 -- Thomson Reuters I/B/E/S.Rexahn Pharmaceuticals - expects its current cash and investments will be sufficient to fund cash flow requirements for current activities into mid-2018.  Full Article

Rexahn Pharma's cash and investments totaled about $20.3 mln as of Dec 31, 2016
Monday, 27 Feb 2017 09:00am EST 

Rexahn Pharmaceuticals Inc : Rexahn Pharmaceuticals reports full year 2016 financial results and provides corporate update .Rexahn Pharmaceuticals Inc - Rexahn's cash and investments totaled approximately $20.3 million as of December 31, 2016.  Full Article

Rexahn Pharmaceuticals Q2 loss per share $0.01
Monday, 8 Aug 2016 09:00am EDT 

Rexahn Pharmaceuticals Inc : Rexahn Pharmaceuticals reports second quarter 2016 financial and operational results . Q2 loss per share $0.01 .Expects current cash, investments sufficient to fund co's cash flow requirements for activities into second half of 2017.  Full Article

Rexahn Pharma Q1 loss per share $0.02
Monday, 9 May 2016 09:00am EDT 

Rexahn Pharmaceuticals Inc : Expects cash investments as of march 31, 2016 will be sufficient to fund requirements for current activities into h2 2017 . Rexahn pharmaceuticals reports first quarter 2016 financial results and provides corporate update .Q1 loss per share $0.02.  Full Article

Rexahn Pharmaceuticals announces new data for Supinoxin Showing Potent Tumor Growth Inhibition
Monday, 14 Dec 2015 09:00am EST 

Rexahn Pharmaceuticals Inc:Announced that it presented new preclinical data for its anti-cancer compound, Supinoxin (RX-5902).Results demonstrated oral administration of ascending weekly doses of supinoxin showed dose-dependent, potent tumor growth inhibition.  Full Article

Rexahn Pharmaceuticals, Inc announces $7 mln registered direct offering
Friday, 6 Nov 2015 09:00am EST 

Rexahn Pharmaceuticals, Inc:Announces $7.0 million registered direct offering.Says net proceeds of the offering will be used for further development of rexahn's lead clinical programs.Entered into agreement with institutional investor to purchase about 16.7 million shares of its common stock.  Full Article

BRIEF-Rexahn Pharmaceuticals receives new U.S. patent for Supinoxin

* Rexahn Pharmaceuticals receives new U.S. patent for Supinoxin Source text for Eikon: Further company coverage: